Odulimomab

Drug Profile

Odulimomab

Alternative Names: 25.3; 25.3 monoclonal antibody; Anti-CD11a monoclonal antibody 25.3; Anti-LFA-1 monoclonal antibody; Antilfa

Latest Information Update: 22 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunotech
  • Developer Immunotech; Sanofi Genzyme
  • Class Monoclonal antibodies
  • Mechanism of Action CD11a antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease; Renal transplant rejection
  • Discontinued Delayed graft function

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 08 May 2003 Discontinued - Preclinical for Diabetes mellitus in Japan (Intraperitoneal)
  • 13 Dec 2000 SangStat has discontinued development of odulimomab for the transplant indication in Europe and North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top